Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Chronic lymphocytic leukemia (CLL)

One year of first-line therapy for CLL for the prospect of more than 5 years of treatment freedom¹

    • Oncology
    • Partner Content
    • RX
  • 4 minute read

The BCL2 inhibitor venetoclax has been approved in Switzerland as a first-line therapy for chronic lymphocytic leukemia (CLL) since November 16, 2023 [2]. This is based on the results of the CLL14 study, the 6-year data of which were presented at the European Hematology Association Congress in Frankfurt on June 9, 2023 [1]. The data give CLL patients the prospect of more than 5 years of treatment freedom after less than one year of combined treatment with venetoclax and obinutuzumab [1, 2].

The combination of chlorambucil (Clb) + obinutuzumab (Obi) was considered the standard of care in the first-line treatment of CLL, but the BCL2 inhibitor Venclyxto® (Ven) has also shown good efficacy in the past in second-line treatment after at least one prior treatment [3, 4]. In the randomized, multicenter, open-label Phase III CLL14 study, first-line treatment with Ven + Obi was tested in comparison to Clb + Obi over a fixed period of time in patients with previously untreated CLL and additional comorbidities. Ven + Obi showed a significant advantage in progression-free survival (PFS) [5]. Updated efficacy and safety data are now available from the ongoing follow-up of the CLL14 study, whereby at this point all patients have not received the study drug for ≥ 5 years [1].

Consistently high PFS rates with Venclyxto®

A total of 432 patients with previously untreated CLL and additional comorbidities were included in the CLL14 study, with study participants randomized 1:1 to receive either 12 cycles of Ven with 6 cycles of Obi (Ven-Obi, n=216), or 12 cycles of Clb with 6 cycles of Obi (Clb-Obi, n=216) [1]. The median follow-up time in the updated follow-up study was 76.4 months (interquartile range 52.5-80.5) [1]. During follow-up, the median PFS in the Ven-Obi arm remained superior at 76.2 months compared to 36.4 months in the Clb-Obi arm (HR = 0.40; 95% CI [0,31-0,52], p<0.0001). The estimated PFS rate according to the investigators was 53.1 % in the Ven-Obi group and 21.7 % in the Clb-Obi arm 6 years after randomization [1].

With Venclyxto® for long-lasting freedom from therapy

In the Ven-Obi group, 67 patients experienced disease progression (PD) and 39 second-line treatments, while 141 cases of PD occurred in the Clb-Obi group. 103 of these patients underwent second-line treatment [1]. The time to next treatment (TTNT) after 6 years of follow-up was 65.2 % in the Ven-Obi arm and 37.1 % after Clb-Obi (HR = 0.44; 95% CI [0,33-0,58], p<0.0001; Figure 1) [1]. Second-line treatment with Ven (monotherapy or in combination with rituximab) took place in 17.9% of patients after Ven-Obi and in 14.6% after Clb-Obi [1].

High survival rates even ≥ 5 years after the end of treatment

The 6-year overall survival rate was 78.7% after Ven-Obi treatment and 69.2% after Clb-Obi treatment (HR = 0.69; 95% CI [0,48-1,01], p=0.052), with 48 deaths in the Ven-Obi arm and 70 in the Clb-Obi arm [1]. Second primary malignancies were reported in 30 patients in the Ven-Obi arm and 18 in the Clb-Obi arm.

Previous studies have shown no differences in tolerability between the two treatment regimens and no new safety signals have emerged even after 6 years of follow-up [1, 5]. The most common adverse events (≥ 20%, all grades) in patients treated with Ven in the combination study with Obi were neutropenia, diarrhea and thrombocytopenia [1,2].

Conclusion

Overall, the updated data confirm a long-term PFS benefit of Ven-Obi treatment compared to Clb-Obi [1]. In addition, around 65% of patients treated with Ven-Obi still did not require second-line treatment ≥ 5 years after treatment, which underlines the long-term effect of the Ven-Obi first-line therapy regimen and allows patients valuable treatment-free time [1].

Areas of application of VENCLYXTO®

VENCLYXTO® in combination with obinutuzumab is approved for the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL) and additional comorbidities [2]. VENCLYXTO® is approved in combination with rituximab in CLL patients after at least one prior therapy and is reimbursed by health insurance companies [2, 6]. VENCLYXTO® is also used as a monotherapy for CLL patients with a del(17p) or TP53 mutation following treatment failure with a B-cell receptor signaling pathway inhibitor. VENCLYXTO® is also available in combination with azacitidine, decitabine or low-dose cytarabine for adult patients with newly diagnosed acute myeloid leukemia (AML) for whom intensive chemotherapy is not an option [2].

Figure 1) Time to next anti-CLL treatment (TTNT) 5 years after end of therapy (EoT) with Venclyxto®+ obinutuzumab (Ven-Obi; yellow) and chlorambucil + obinutuzumab (Clb-Obi; gray).
* 336 days in first-line therapy with Ven-Obi [2]. Adapted from Al Sawaf O. et al, 2023 [1].

Abbreviations:

HR: Hazard Ratio; CI = Confidence Interval

Brief technical information on VENCLYXTO®

This article was produced with the financial support of AbbVie AG, Alte Steinhauserstrasse 14, Cham.

CH-VNCLY-230063 11/2023

Literature

1 Al-Sawaf, O., et al, Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study. Abstract S145 (Oral). European Hematology Association Congress 2023, June 8-11 Frankfurt, Germany.
2. current technical information Venclyxto® . www.swissmedicinfo.ch .
3 Eichhorst, B., et al, appendix 6: Chronic lymphocytic leukemia: eUpdate published online September 2016 ( http://www.esmo.org/Guidelines/Haematological-Malignancies ). Ann Oncol, 2016. 27(suppl 5): p. v143-v144.
4 Fischer, K., et al, Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood, 2017. 129(19): p. 2702-2705.
5 Fischer, K., et al, Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med, 2019. 380(23): p. 2225-2236.
6. Specialty list Venclyxto®. Federal Office of Public Health. www.spezialitaetenliste.ch. Status of the information: 06.07.2023.

The references can be requested by professionals at medinfo.ch@abbvie.com.

Partner
  • abbvielogo_preferred_coatedcmyk
Related Topics
  • lymphatic leukemia
  • Oncology
Previous Article
  • Aspirin-free strategy after PCI

No reduction in bleeding (STOPDAPT-3 study)

  • Cardiology
  • Congress Reports
  • RX
  • Studies
View Post
Next Article
  • Prurigo nodularis

Inflammation-promoting pruritogenic cytokines as a therapeutic target

  • Allergology and clinical immunology
  • Congress Reports
  • Dermatology and venereology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 3 min
  • Public Health

Outpatient care in Switzerland: situation report

    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
View Post
  • 5 min
  • Practice Management

Improved quality of care aims for satisfied patients

    • CME continuing education
    • General Internal Medicine
    • Practice Management
    • Prevention and health care
    • RX
    • Studies
View Post
  • 30 min
  • Chemsex - MSM, sex, chrystal meth & co.

Medical and psychosocial perspectives

    • CME continuing education
    • General Internal Medicine
    • Infectiology
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • RX
View Post
  • 3 min
  • Bladder cancer

Tuberculosis vaccination reduces recurrences

    • Congress Reports
    • Oncology
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
    • Urology
View Post
  • 4 min
  • Oral JAK-i in atopic dermatitis

Benefits and risks: What does the current data say?

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
    • Studies
View Post
  • 9 min
  • Chronic lung diseases

Sarcopenia and malnutrition in the context of pneumological rehabilitation

    • CME continuing education
    • General Internal Medicine
    • Geriatrics
    • Nutrition
    • Pneumology
    • RX
    • Sports Medicine
    • Studies
View Post
  • 17 min
  • Sleep-wake disorders in pneumology practice

Patience, knowledge and persistence in therapy

    • CME continuing education
    • General Internal Medicine
    • Neurology
    • Pneumology
    • RX
View Post
  • 19 min
  • Cardiovascular risk and obesity

Pathomechanisms, secondary prevention and treatment options

    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • Nutrition
    • RX
    • Sports Medicine
    • Studies
    • Training with partner
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.